Strive increased its Bitcoin holdings by purchasing 3,311 BTC between October 5 and 9, raising its total to 32,773 BTC. CEO Matt Cole announced that holders exercised $208 million worth of warrants before their expiry on October 13, with about 15.3 million shares still outstanding. Additionally, Strive made a $100 minimum sale price for its SATA preferred shares a binding rule to protect shareholder value. These moves highlight Strive's strategy to strengthen its Bitcoin treasury and maintain financial stability as warrant expirations approach.
Strive's recent Bitcoin purchase and warrant activity provide context for cryptocurrency trends. For readers following crypto markets, here is Pluang's market snapshot as of Oct 13, 2026 20:51 WIB: out of 50 major cryptocurrencies, 7 rose and 42 fell. Notable movers include EOS with an 8.13% gain, ONE down 9.13%, and AXS down 7.42%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
